Filing Flows › C4 Therapeutics (CCCC) › Q2 2025
C4 Therapeutics (CCCC) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 7, 2025
C4 Therapeutics (CCCC) reported revenue of $6.5M for the second quarter 2025 (Q2 2025), -46% from a year earlier and -11% from the quarter before. Operating margin was -441.0%, net loss $26.0M (402.6% of revenue).
C4 Therapeutics, Q2 2025: revenue $6.5M (-46% year over year), operating margin -441.0%, net loss $26.0M, operating cash flow −$12.1M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $6.5M | -11% | -46% |
| Operating profit | −$28.5M | — | — |
| Net earnings | −$26.0M | — | — |
| Operating cash flow | −$12.1M | — | — |
What changed
Revenue was $6.5M in Q2 2025, down 46% year over year and down 11% from the previous quarter.
Operating costs exceeded revenue by $28.5M, an operating margin of -441.0%. Total costs grew 5% against a revenue fall of 46%. The fastest-growing cost line was Research & development (+10%). The quarter ended with a net loss of $26.0M, narrower than the previous quarter's $26.3M loss.
Operating cash flow was −$12.1M. Non-cash charges added back $615K of depreciation and amortization and $5.0M of share-based compensation. Working capital and other items added $8.4M. Capital expenditures of $185K exceeded it, leaving free cash flow of −$12.2M.
Questions
What was C4 Therapeutics' revenue in the second quarter 2025?
C4 Therapeutics (CCCC) reported revenue of $6.5M for the second quarter 2025 (Q2 2025), -46% from a year earlier and -11% from the quarter before.
Was C4 Therapeutics profitable in the second quarter 2025?
Operating loss was $28.5M (-441.0% of revenue) and net loss $26.0M.
Source: C4 Therapeutics 10-Q on SEC EDGAR.